Costs and Resource Utilization Among Medicaid Patients with Schizophrenia Treated with Paliperidone Palmitate or Oral Atypical Antipsychotics
about
Adherence, healthcare resource utilization and Medicaid spending associated with once-monthly paliperidone palmitate versus oral atypical antipsychotic treatment among adults recently diagnosed with schizophreniaPharmacoeconomic comparison of aripiprazole once-monthly and paliperidone palmitate from a head-to-head clinical trial in schizophrenia: a US analysisHealth care resource utilization and costs of California Medicaid patients with schizophrenia treated with paliperidone palmitate once monthly or atypical oral antipsychotic treatment.Economic Impact in Medicaid Beneficiaries with Schizophrenia and Cardiometabolic Comorbidities Treated with Once-Monthly Paliperidone Palmitate vs. Oral Atypical Antipsychotics.Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder.
P2860
Costs and Resource Utilization Among Medicaid Patients with Schizophrenia Treated with Paliperidone Palmitate or Oral Atypical Antipsychotics
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Costs and Resource Utilization ...... r Oral Atypical Antipsychotics
@en
type
label
Costs and Resource Utilization ...... r Oral Atypical Antipsychotics
@en
prefLabel
Costs and Resource Utilization ...... r Oral Atypical Antipsychotics
@en
P2093
P2860
P1476
Costs and Resource Utilization ...... r Oral Atypical Antipsychotics
@en
P2093
David M Smith
Erik Muser
Jacqueline A Pesa
Oren I Meyers
P2860
P2888
P304
P356
10.1007/S40801-015-0043-4
P577
2015-10-13T00:00:00Z
P6179
1051696695